52121-36-5

Basic information

• Product Name: 3-Bromo-4-ethylbenzenamine
• Synonyms: 3-Bromo-4-ethylbenzenamine;3-Bromo-4-ethylaniline;3-Bromo-4-ethylphenylamine
• CAS NO: 52121-36-5
• Molecular Formula: C₈H₁₀BrN
• Molecular Weight: 200
• Mol File: 52121-36-5.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 270℃
• Flash Point: 117℃
• Appearance: /
• Density: 1.421
• PKA: 4.01±0.10(Predicted)
• CAS DataBase Reference: 3-Bromo-4-ethylbenzenamine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Bromo-4-ethylbenzenamine(52121-36-5)
• EPA Substance Registry System: 3-Bromo-4-ethylbenzenamine(52121-36-5)

Safety Data

• Hazardous Substances Data: 52121-36-5(Hazardous Substances Data)

Usage

General Description

3-Bromo-4-ethylbenzenamine is a chemical compound, categorized as an aromatic amine, that is used mainly in the field of organic synthesis. 3-Bromo-4-ethylbenzenamine is characterized by the presence of a bromine atom and an ethyl group attached to a benzene ring, with an amine group (-NH2) attached additionally. The key properties include its molecular formula: C8H10BrN, molecular weight: 200.08, density: 1.3±0.1 g/cm^3, and boiling point: 278.2±25.0 °C at 760 mmHg. It's generally colorless to light yellow in appearance and is often in the liquid state at room temperature. Like many chemicals, it requires careful handling, as exposure can be harmful. Thus, it is predominantly used in controlled environments like research and industrial labs.

Upstream product

• 20191-74-6 2-ethyl-5-nitroaniline 
• 100-12-9 4-ethylnitrobenzene 
• 52121-34-3 2-bromo-1-ethyl-4-nitrobenzene 

Downstream Products

• 52121-38-7 3-bromo-4-ethyl-6-nitroaniline 
• 186666-73-9 (5-Bromo-4-ethyl-2-nitro-phenylamino)-acetic acid ethyl ester 
• 186666-72-8 N-(5-Bromo-4-ethyl-2-nitro-phenyl)-2,2,2-trifluoro-acetamide 
• 1445789-64-9 diethyl 2-((3-bromo-4-ethylphenylamino)methylene)malonate 
• 1445789-74-1 C₃₁H₃₃N₅O₅ 
• 1445789-70-7 methyl 3-(7-bromo-3-carbamoyl-6-ethylquinolin-4-ylamino)-5-cyclopentylbenzoate 
• 1445786-78-6 3-((3-carbamoyl-7-(2,4-dimethoxypyrimidin-5-yl)-6-ethylquinolin-4-yl)amino)-5-cyclopentylbenzoic acid 
• 355013-43-3 5-(3-bromo-4-ethyl-anilino)-8-[(6-methoxy-pyridin-3-yl)-methyl]-[1,6]naphthyridine 
• 147150-13-8 6-bromo-5-ethylanthranilic acid 
• 852946-96-4 2-bromo-1-ethyl-4-methoxybenzene 
• 878487-84-4 α-(2-ethyl-5-methoxyphenyl)acetophenone 

Relevant articles and documents

PHARMACEUTICAL COMPOSITION AND APPLICATION REPLACING QUINOLONE DERIVATIVE, PHARMACEUTICAL ACCEPTABLE SALT, OR STEREOISOMER

Provided are a substituted quinolone derivative as shown by formula (I), or a pharmaceutically acceptable salt and a prodrug molecule thereof, and a pharmaceutical composition thereof, as well as the use of same in preparing drugs for the prevention and treatment of a tumor. The quinolone derivative, salt, prodrug molecule, and pharmaceutical composition thereof can be used as a protein kinase inhibitor, which is effective in inhibiting the activity of AXL protein kinase, and is capable of inhibiting the proliferation, migration and invasion of various tumor cells; and can be used in the preparation of anti-tumor drugs, especially drugs for treating hyperproliferative diseases such as a tumor in human beings and other mammals.

COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

Electronic effects of ring substituents on triplet benzylic biradicals

UV irradiation of α-(o-alkylphenyl)acetophenones with a methoxy or cyano substituent para to the o-alkyl group of the α-aryl ring has revealed that a methoxy group slightly increases the stereoselectivity but not the quantum yield of indanol formation, whereas a cyano group greatly lowers both diastereoselectivity and quantum efficiency, confirming the likelihood that hydrogen-bonding of the hydroxy group to the α-phenyl ring plays an important role in the cyclization of the photogenerated triplet 1,5-biradical intermediates.